Rigel Posts Record Q2 Product Sales, Raises 2026 Revenue Outlook to $295M
RIGL sits 83% above its 52-week low of $21.81.
Summary
Rigel delivered a strong Q2 with net product sales of $67M, up 14% YoY, and net income of $17.3M. The company raised its full-year 2026 revenue guidance to $285-$295M, driven by core product growth and the upcoming launch of newly in-licensed breast cancer drug VEPPANU, expected mid-August. This follows the exclusive global licensing deal for VEPPANU announced in May and closed in June. The pipeline also advanced: R289 Phase 1b in lower-risk MDS remains on track for dose selection and preliminary data by year-end. The raised outlook and imminent launch of a first-in-class PROTAC therapy materially improve the commercial profile.
At the time of this announcement, RIGL was trading at $39.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $716M. The 52-week trading range was $21.81 to $52.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.